ERGO (Entia Biosciences) EBITDA Margin %: -839.13% (As of Dec. 2016)

What is Entia Biosciences EBITDA Margin %?

Entia Biosciences ERGO EBITDA Margin % is -839.13% as of Dec. 2016.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Entia Biosciences's EBITDA for the three months ended in Dec. 2016 was $-0.39 Mil. Entia Biosciences's Revenue for the three months ended in Dec. 2016 was $0.05 Mil. Therefore, Entia Biosciences's EBITDA margin for the quarter that ended in Dec. 2016 was -839.13%.

Entia Biosciences (OTCPK:ERGO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Entia Biosciences EBITDA Margin % Related Terms

Entia Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences EBITDA Margin % Chart

Entia Biosciences Annual Data

Trend

Jul07

Jul08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

EBITDA Margin %

Get a 7-Day Free Trial

-265.58

-928.25

-292.53

-592.22

-488.68

Entia Biosciences Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
EBITDA Margin %	Get a 7-Day Free Trial															-391.18	-329.11	-386.73	-640.48	-839.13

ERGO vs OBMP, NSPX, ATRX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Entia Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entia Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entia Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Entia Biosciences's EBITDA Margin % falls into.

Save Embed

Entia Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Entia Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2016 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2016 )	/	Revenue (A: Dec. 2016 )
	=	-1.295	/	0.265
	=	-488.68 %

Entia Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2016 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2016 )	/	Revenue (Q: Dec. 2016 )
	=	-0.386	/	0.046
	=	-839.13 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -839.13% mean?

Entia Biosciences (ERGO) has a EBITDA Margin % of -839.13% as of Dec. 2016. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Entia Biosciences and its competitors.

Is Entia Biosciences' EBITDA Margin % too high?

Entia Biosciences' current EBITDA Margin % is -839.13%.

How does Entia Biosciences' EBITDA Margin % compare to OBMP and NSPX?

Entia Biosciences' EBITDA Margin % of -839.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Entia Biosciences and its competitors. Entia Biosciences's current EBITDA Margin % is -839.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Entia Biosciences stock overvalued right now?

Entia Biosciences (ERGO) has a current EBITDA Margin % of -839.13%. The current EBITDA Margin % is -839.13%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current EBITDA Margin % is -839.13% as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies BOM:506365 OBMP NSPX BOM:532041 ATRX PPCB WAR:PFM RSPI TSXV:MFS BOM:542765 HSTC CAPS ATMS AKAOQ BRTX TSXV:PBS BOM:532871 APOP TSXV:APC ONTX

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140

Website http://www.entiabio.com

Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.